Big Pharma Split Stock Buy Hold or Sell Recommendation
| PRM Stock | CAD 13.30 0.18 1.37% |
Assuming the 90 days trading horizon and your above-average risk tolerance, our recommendation regarding Big Pharma Split is 'Sell'. The recommendation algorithm takes into account all of Big Pharma's available fundamental, technical, and predictive indicators you will find on this site.
Check out Big Pharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Big and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Big Pharma Split. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Big |
Execute Big Pharma Buy or Sell Advice
The Big recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Big Pharma Split. Macroaxis does not own or have any residual interests in Big Pharma Split or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Big Pharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Big Pharma Trading Alerts and Improvement Suggestions
| Big Pharma Split generated a negative expected return over the last 90 days | |
| Big Pharma Split has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 311.76 K. Net Loss for the year was (645.35 K) with profit before overhead, payroll, taxes, and interest of 5.56 M. | |
| Latest headline from news.google.com: Harvest Declares Big Pharma Split Corp. November 2024 Distribution - Yahoo Finance |
Big Pharma Returns Distribution Density
The distribution of Big Pharma's historical returns is an attempt to chart the uncertainty of Big Pharma's future price movements. The chart of the probability distribution of Big Pharma daily returns describes the distribution of returns around its average expected value. We use Big Pharma Split price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Big Pharma returns is essential to provide solid investment advice for Big Pharma.
| Mean Return | -0.14 | Value At Risk | -2.27 | Potential Upside | 1.54 | Standard Deviation | 1.00 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Big Pharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Big Pharma Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 119.0K | (305.1K) | 1.2M | (610.6K) | (615.0K) | (584.3K) | |
| Free Cash Flow | 8.7M | 4.3M | (9.0M) | 1.1M | 11.9M | 12.5M | |
| Change In Working Capital | (3.0K) | (31.7K) | (154.3K) | 175.4K | 9.7K | 10.1K | |
| Begin Period Cash Flow | 417.1K | 536.1K | 231.0K | 1.4M | 819.2K | 829.5K | |
| Other Cashflows From Financing Activities | (6.3M) | (3.0M) | 11.5M | 962.3K | (10.5M) | (10.0M) | |
| Other Non Cash Items | 6.1M | 4.6M | (13.1M) | (1.4M) | 12.5M | 13.1M | |
| Dividends Paid | 1.5M | 1.2M | 2.2M | 1.9M | 2.1M | 1.5M | |
| Total Cash From Operating Activities | 8.7M | 4.3M | (9.0M) | 1.1M | 11.9M | 12.5M | |
| Change To Operating Activities | (54.0K) | (3.0K) | (31.7K) | (154.3K) | (138.9K) | (131.9K) | |
| Net Income | 2.6M | (217.4K) | 4.2M | 2.4M | (645.4K) | (613.1K) | |
| Total Cash From Financing Activities | (8.6M) | (4.7M) | 10.2M | (1.7M) | (12.5M) | (11.8M) | |
| End Period Cash Flow | 536.1K | 231.0K | 1.4M | 819.2K | 204.2K | 194.0K | |
| Change To Netincome | (780.2K) | 6.1M | 4.6M | (13.1M) | (15.0M) | (15.8M) |
Big Pharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Big Pharma or Capital Markets sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Big Pharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Big stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.15 | |
β | Beta against Dow Jones | 0.01 | |
σ | Overall volatility | 1.02 | |
Ir | Information ratio | -0.27 |
Big Pharma Volatility Alert
Big Pharma Split exhibits very low volatility with skewness of -0.94 and kurtosis of 2.24. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Big Pharma's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Big Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Big Pharma Fundamentals Vs Peers
Comparing Big Pharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Big Pharma's direct or indirect competition across all of the common fundamentals between Big Pharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Big Pharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Big Pharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Big Pharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Big Pharma to competition |
| Fundamentals | Big Pharma | Peer Average |
| Return On Equity | -0.0363 | -0.31 |
| Return On Asset | -0.0069 | -0.14 |
| Profit Margin | (2.01) % | (1.27) % |
| Operating Margin | 0.51 % | (5.51) % |
| Current Valuation | (9.41 M) | 16.62 B |
| Shares Outstanding | 1.13 M | 571.82 M |
| Number Of Shares Shorted | 100 | 4.71 M |
| Price To Book | 0.95 X | 9.51 X |
| Price To Sales | 46.87 X | 11.42 X |
| Revenue | 311.76 K | 9.43 B |
| Gross Profit | 5.56 M | 27.38 B |
| EBITDA | (139.68 K) | 3.9 B |
| Net Income | (645.35 K) | 570.98 M |
| Total Debt | 10.3 M | 5.32 B |
| Book Value Per Share | 13.99 X | 1.93 K |
| Cash Flow From Operations | 11.86 M | 971.22 M |
| Short Ratio | 1.19 X | 4.00 X |
| Earnings Per Share | 0.99 X | 3.12 X |
| Target Price | 2.0 | |
| Beta | 0.88 | -0.15 |
| Market Capitalization | 15.04 M | 19.03 B |
| Total Asset | 26.53 M | 29.47 B |
| Annual Yield | 0.09 % | |
| Net Asset | 26.53 M | |
| Last Dividend Paid | 1.24 |
Big Pharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Big . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Daily Balance Of Power | 9.2 T | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 13.3 | |||
| Day Typical Price | 13.3 | |||
| Price Action Indicator | 0.09 | |||
| Period Momentum Indicator | 0.18 | |||
| Relative Strength Index | 19.67 |
About Big Pharma Buy or Sell Advice
When is the right time to buy or sell Big Pharma Split? Buying financial instruments such as Big Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Big Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Small Cap ETFs Thematic Idea Now
Small Cap ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Small Cap ETFs theme has 167 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Cap ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Big Stock
Big Pharma financial ratios help investors to determine whether Big Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Big with respect to the benefits of owning Big Pharma security.